Journal article icon

Journal article

Rational design of a chimpanzee adenoviral-vector vaccine against yellow fever through the modification of antigen transmembrane domains

Abstract:
Background/Objectives:
Chimpanzee adenoviral-vectored vaccines have proven to be both safe and effective, with a manufacturing and distribution pipeline capable of rapid global supply, as demonstrated during the COVID-19 pandemic. Yellow fever is a mosquito-borne viral hemorrhagic disease endemic in parts of Africa and Latin America, and although an effective live attenuated vaccine exists, its use is limited by safety and eligibility restrictions. Moreover, large outbreaks continue to expose critical challenges, such as an insufficient vaccine supply, reliance on fractional dosing, and slow and difficult-to-scale manufacturing processes. Here, we report the design, development and in vivo immunogenicity of multiple yellow fever virus (YFV) antigen constructs based on the pre-membrane (prM) and envelope (E) proteins—with or without the transmembrane domain (TM or ΔTM)—delivered using the ChAdOx1 adenoviral vector.
Methods:
Four ChAdOx1 YF vaccines were developed, and immunogenicity was evaluated. The efficacy of the full-length YF envelope vaccine was also tested in Balb/c mice.
Results/Conclusions:
In contrast to previously described orthoflavivirus vaccines on the same platform, the full-length antigen elicited superior immunogenicity and conferred protection against intracranial challenge with the YF17D virus in mice. Notably, this protection was comparable to that induced by the licensed YF17D vaccine, highlighting the promise of this platform as a next-generation yellow fever vaccine candidate.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.3390/vaccines14030273

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Pandemic Sciences Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Pandemic Sciences Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Pandemic Sciences Institute
Role:
Author
ORCID:
0009-0000-1813-0557
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Pandemic Sciences Institute
Role:
Author


More from this funder
Funder identifier:
https://ror.org/019w4f821
Grant:
101137459 (Yellow4FLAVI)
Programme:
Horizon Europe Programme
More from this funder
Funder identifier:
https://ror.org/00k4n6c32


Publisher:
MDPI
Journal:
Vaccines More from this journal
Volume:
14
Issue:
3
Article number:
273
Place of publication:
Switzerland
Publication date:
2026-03-20
Acceptance date:
2026-03-18
DOI:
EISSN:
2076-393X
Pmid:
41893809


Language:
English
Keywords:
Pubs id:
2395875
Local pid:
pubs:2395875
Source identifiers:
W7138989587
Deposit date:
2026-04-01
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP